Pharmaphorum has recently published an article from The Planning Shop titled ‘Balancing cost:benefit in ‘well-treated’ malignancies’. The article was written by Jeremy Smith, an Associate Director based in our US office.
Jeremy discusses the cost:benefit ratio of the rising prices of new oncology treatments and how the pharmaceutical industry and regulators can adequately address them while still promoting R&D.
You can read the article by clicking here.
Please contact us on [email protected] or 020 8231 6888 if you’d like more information.